Access Cell Culture 人AB血清(535-HI GI)-細胞/細菌培養(yǎng)-試劑-生物在線

女人与狗锁死了视频大全|霍金死亡过程恐怖视频|无节社团简谱季免费观看|六间房直播大厅|中文字幕欧美另类精品|久久人人玩人妻潮喷内射人人|亚洲国产一区二区三区在线观看

上海睿通生物科技有限公司
Access Cell Culture 人AB血清(535-HI GI)

Access Cell Culture 人AB血清(535-HI GI)

商家詢價

產(chǎn)品名稱: Access Cell Culture 人AB血清(535-HI GI)

英文名稱: Human Male AB Plasma-Derived serum

產(chǎn)品編號: 535-HI GI

產(chǎn)品價格: 0

產(chǎn)品產(chǎn)地: 美國

品牌商標: Access Cell Culture

更新時間: 2023-08-13T18:51:06

使用范圍: null

上海睿通生物科技有限公司
  • 聯(lián)系人 : 睿通生物
  • 地址 : 上海市寶山區(qū)大場鎮(zhèn)滬太路2999弄13號2層
  • 郵編 : 200436
  • 所在區(qū)域 : 上海
  • 電話 : 132****5728 點擊查看
  • 傳真 : 點擊查看
  • 郵箱 : info@ruitongbio.com

Human Male AB Plasma-Derived serum can be used for various cell culture applications.


It is a main component needed for culturing human cell lines. It is often used to replace FBS which is not an ideal supplement for human derived cell lines. Human Male AB Serum is filtered and cell culture tested for mycoplasma, endotoxin, and sterility.


The Access Advantage:


Our Human Male AB Plasma-Derived Serum is a proprietary product manufactured with either human or bovine thrombin following a cGMP process.

We collect and manufacture internally, allowing us to offer a product using a fully closed-loop system from plasma donation to finished product.


Access Biologicals directly collects our plasma from FDA licensed centers within the US


Each unit is tested and found negative for all viral markers using FDA-approved methods

Testing at CLIA and FDA approved labs

HIV-1, HCV and HBV by Nucleic Acid Test, Parvo B19 and HAV by Nucleic Acid Test, Anti-HIV 1 / 2, Anti-HCV, HBsAg & Syphilis

Additional testing provided by Access: Zika, Chagas, WNV, Anti HBC, Mycoplasma, Endotoxin, USP Sterility, Hemoglobin, Osmolality, pH, Chemistry, and Species Testing

Additional testing available upon request

.1μm sterile-filtered

Custom donor pools available


Heat inactivation and gamma irradiation available upon request

Gamma irradiation is through a validated process

Virus validation study completed March 2019